Supplementary Table 2. Types of previous antiplatelet medications in patients with and without ICAS

Medications	Total (n=701)	ICAS (n=336)	Non-ICAS (n=365)	*P*
One type				
Aspirin	667 (95.2)	317 (94.4)	350 (95.9)	0.905
Clopidogrel	19 (2.7)	11 (3.3)	8 (2.2)	0.378
Ticagrelor	2 (0.3)	1 (0.3)	1 (0.3)	0.411
Dipyridamole	0	0	0	NA
Cilostazol	0	0	0	NA
Other antiplatelet drugs	6 (0.9)	3 (0.9)	3 (0.8)	0.999
Two types				
Aspirin+Clopidogrel	6 (0.9)	3 (0.9)	3 (0.8)	0.999
Aspirin+Other	1 (0.1)	1 (0.3)	0	0.479

Values are presented as n (%).
ICAS, intracranial artery stenosis; NA, not applicable.

Supplementary Table 3. Effect of ticagrelor-aspirin compared with clopidogrel-aspirin on clinical outcomes within 1 year stratified by previous antiplatelet therapy in the overall subgroup patients

Outcomes	CA	TA	Crude HR (95% CI)	Adjusted HR (95% CI)*	Adjusted *P* for interaction*
Stroke					0.197
Without Pap	263 (10.1)	190 (7.3)	0.71 (0.59–0.86)	0.70 (0.58–0.85)	
With Pap	35 (10.2)	36 (10.0)	0.97 (0.61–1.54)	1.00 (0.62–1.59)	
Composite vascular events†					0.123
Without Pap	319 (12.2)	229 (8.8)	0.70 (0.59–0.83)	0.70 (0.59–0.83)	
With Pap	43 (12.7)	45 (12.5)	0.99 (0.65–1.50)	1.02 (0.67–1.56)	
Ischemic stroke					0.215
Without Pap	253 (9.7)	185 (7.1)	0.72 (0.59–0.87)	0.71 (0.59–0.86)	
With Pap	35 (10.3)	36 (10.0)	0.97 (0.61–1.54)	1.00 (0.62–1.59)	
Disabling stroke‡					0.575
Without Pap	82 (3.1)	75 (2.9)	0.90 (0.66–1.23)	0.88 (0.65–1.21)	
With Pap	13 (3.8)	16 (4.4)	1.16 (0.56–2.41)	1.25 (0.60–2.61)	
Severe or moderate bleeding§					0.265
Without Pap	18 (0.7)	14 (0.5)	0.78 (0.39–1.56)	0.79 (0.39–1.58)	
With Pap	1 (0.3)	2 (0.6)	1.87 (0.17–20.62)	2.17 (0.19–25.02)	
Any bleeding					0.918
Without Pap	78 (3.0)	151 (5.8)	1.96 (1.49–2.58)	1.97 (1.50–2.58)	
With Pap	11 (3.2)	23 (6.4)	2.00 (0.97–4.10)	2.02 (0.98–4.16)	

Values are presented as n (%) unless otherwise indicated.
CA, clopidogrel-aspirin; TA, ticagrelor-aspirin; HR, hazard ratio; CI, confidence interval; Pap, previous antiplatelet therapy; TIA, transient ischemic attack; mRS, modified Rankin Scale.
*Adjusted for age, Han ethnic, sex, body mass index, current smoking status, medical history of hypertension, diabetes, dyslipidemia, myocardial infarction, ischemic stroke, TIA, type of *CYP2C19* loss-of-function allele carrier, and previous lipid-lowering therapy; †Composite vascular events include ischemic stroke, hemorrhagic stroke, TIA, myocardial infarction, and vascular death; ‡A stroke was defined as disabling if the patient had an mRS score of greater than 1 (indicating death or any degree of disability); §Severe or moderate bleeding were defined according to Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) criteria.

https://doi.org/10.5853/jos.2025.00213